Immunovant, Inc. (NASDAQ:IMVT – Get Free Report) insider Mark S. Levine sold 2,505 shares of the firm’s stock in a transaction dated Wednesday, July 17th. The shares were sold at an average price of $29.69, for a total transaction of $74,373.45. Following the transaction, the insider now directly owns 337,409 shares in the company, valued at approximately $10,017,673.21. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.
Immunovant Price Performance
Shares of IMVT stock opened at $27.97 on Monday. The stock’s fifty day moving average price is $27.84 and its 200 day moving average price is $31.93. Immunovant, Inc. has a 1-year low of $18.82 and a 1-year high of $45.58. The company has a market cap of $4.09 billion, a price-to-earnings ratio of -14.72 and a beta of 0.67.
Immunovant (NASDAQ:IMVT – Get Free Report) last issued its quarterly earnings results on Wednesday, May 29th. The company reported ($0.52) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.08). During the same period last year, the firm posted ($0.46) earnings per share. As a group, equities research analysts anticipate that Immunovant, Inc. will post -2.11 earnings per share for the current year.
Institutional Trading of Immunovant
Analyst Upgrades and Downgrades
A number of equities analysts have recently issued reports on the stock. HC Wainwright reiterated a “buy” rating and set a $51.00 price objective on shares of Immunovant in a research note on Thursday, May 30th. Oppenheimer dropped their target price on Immunovant from $50.00 to $46.00 and set an “outperform” rating on the stock in a research report on Monday, June 3rd. Truist Financial reiterated a “buy” rating and issued a $48.00 price target on shares of Immunovant in a report on Monday, March 25th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Immunovant in a research note on Tuesday, June 18th. Fifteen equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has an average rating of “Buy” and a consensus target price of $49.73.
Get Our Latest Report on Immunovant
Immunovant Company Profile
Immunovant, Inc, a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia.
See Also
- Five stocks we like better than Immunovant
- What Does a Gap Up Mean in Stocks? How to Play the Gap
- Why This AI Stock is Rising Despite Tech Sell-Off
- How to Use Stock Screeners to Find Stocks
- Investors Are Moving into Bonds and Small Cap Stocks: Here’s Why
- How the NYSE and NASDAQ are Different, Why That Matters to Investors
- MarketBeat Week in Review – 7/15 – 7/19
Receive News & Ratings for Immunovant Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunovant and related companies with MarketBeat.com's FREE daily email newsletter.